{
    "abstract": "Ovarian juvenile granulosa cell tumors (juvGCT) are rare sex cord-stromal tumors that occur primarily in children and adolescents. This study summarizes the clinical presentation and outcomes of patients with juvGCT.\nPatients were enrolled in the International Ovarian and Testicular Stromal Tumor and/or International Pleuropulmonary Blastoma/DICER1 Registries. Available medical records were abstracted, and pathology was centrally reviewed. Surgical staging was classified using the 2014 International Federation of Gynecology and Obstetrics (FIGO) criteria.\nIn total, 70 patients with juvGCT enrolled and were diagnosed between 2001 and 2024; most patients (81%, 57 of 70) presented with FIGO stage I disease. Adjuvant chemotherapy was given in 30% (21 of 70); all regimens were platinum-based. Three-year event-free survival among patients with stage IA tumors was 80.2% (95% confidence interval [CI], 62.4%-100.0%), IC1 was 87.4 (95% CI, 72.4%-100.0%), IC2-IC3 was 63.6% (95% CI, 40.7%-99.5%), and II-IV was 48% (95% CI, 24.6%-93.8%). Of the patients with recurrent juvGCT with known mitotic index (MI), all had MI greater than 19 mitoses per 10 high power fields (HPF) at diagnosis.\nOutcomes were worse for patients with FIGO stage\u00a0\u2265IC2 disease and for tumors with >19 mitoses per 10 HPF. Given the prognostic significance of MI, the authors strongly recommend the assessment of MI for all juvGCTs. More information about tumor biology is critical to identify which patients may benefit from adjuvant chemotherapy and to facilitate the development of novel therapies.",
    "authors": [
        {
            "affiliation": "International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nInternational Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nCancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.",
            "firstname": "Anne K",
            "initials": "AK",
            "lastname": "Harris"
        },
        {
            "affiliation": "International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nInternational Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nCancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.\nDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.",
            "firstname": "Alexander T",
            "initials": "AT",
            "lastname": "Nelson"
        },
        {
            "affiliation": "Research Institute, Children's Minnesota, Minneapolis, Minnesota, USA.\nDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.",
            "firstname": "Dave",
            "initials": "D",
            "lastname": "Watson"
        },
        {
            "affiliation": "International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nInternational Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nCancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.",
            "firstname": "Paige H R",
            "initials": "PHR",
            "lastname": "Mallinger"
        },
        {
            "affiliation": "International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nInternational Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nCancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.",
            "firstname": "Yoav H",
            "initials": "YH",
            "lastname": "Messinger"
        },
        {
            "affiliation": "Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.",
            "firstname": "A Lindsay",
            "initials": "AL",
            "lastname": "Frazier"
        },
        {
            "affiliation": "Walter Reed National Military Medical Center, Bethesda, Maryland, USA.",
            "firstname": "Allen",
            "initials": "A",
            "lastname": "Stering"
        },
        {
            "affiliation": "Pediatric Hematology/Oncology, Beacon Health System, South Bend, Indiana, USA.",
            "firstname": "Stacy L",
            "initials": "SL",
            "lastname": "Snyder"
        },
        {
            "affiliation": "Pediatric Hematology/Oncology, Northwell Health, New Hyde Park, New York, USA.",
            "firstname": "Carolyn Fein",
            "initials": "CF",
            "lastname": "Levy"
        },
        {
            "affiliation": "Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.",
            "firstname": "Junne",
            "initials": "J",
            "lastname": "Kamihara"
        },
        {
            "affiliation": "Division of Pediatrics, Department of Pediatric Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.",
            "firstname": "Cynthia E",
            "initials": "CE",
            "lastname": "Herzog"
        },
        {
            "affiliation": "Division of Hematology & Oncology, Department of Pediatrics in the College of Medicine, University of Florida, Gainesville, Florida, USA.",
            "firstname": "Joanne",
            "initials": "J",
            "lastname": "Lagmay"
        },
        {
            "affiliation": "Pediatric Oncology, Queensland Children's Hospital, South Brisbane, Queensland, Australia.\nDepartment of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA.",
            "firstname": "Steve",
            "initials": "S",
            "lastname": "Foresto"
        },
        {
            "affiliation": "Children's Medical Center Research Institute, UT Southwestern Medical Center, Dallas, Texas, USA.",
            "firstname": "Kenneth S",
            "initials": "KS",
            "lastname": "Chen"
        },
        {
            "affiliation": "James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.",
            "firstname": "Kyle M",
            "initials": "KM",
            "lastname": "Devins"
        },
        {
            "affiliation": "James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.",
            "firstname": "Robert H",
            "initials": "RH",
            "lastname": "Young"
        },
        {
            "affiliation": "Lauren V. Ackerman Laboratory of Surgical Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.\nResourcePath LLC, Sterling, Virginia, USA.",
            "firstname": "D Ashley",
            "initials": "DA",
            "lastname": "Hill"
        },
        {
            "affiliation": "Lauren V. Ackerman Laboratory of Surgical Pathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.",
            "firstname": "Louis P",
            "initials": "LP",
            "lastname": "Dehner"
        },
        {
            "affiliation": "Hospital Pathology Associates, Minneapolis, Minnesota, USA.",
            "firstname": "Anil K",
            "initials": "AK",
            "lastname": "Tadavarthy"
        },
        {
            "affiliation": "Hospital Pathology Associates, Minneapolis, Minnesota, USA.",
            "firstname": "Jennifer N",
            "initials": "JN",
            "lastname": "Stall"
        },
        {
            "affiliation": "Division of Pediatric Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.",
            "firstname": "Deborah F",
            "initials": "DF",
            "lastname": "Billmire"
        },
        {
            "affiliation": "Clinic of Pediatrics, Municipal Hospital Dortmund, University Witten/Herdecke, Witten, Germany.",
            "firstname": "Dominik T",
            "initials": "DT",
            "lastname": "Schneider"
        },
        {
            "affiliation": "International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nInternational Ovarian and Testicular Stromal Tumor Registry, Children's Minnesota, Minneapolis, Minnesota, USA.\nCancer and Blood Disorders, Children's Minnesota, Minneapolis, Minnesota, USA.",
            "firstname": "Kris Ann P",
            "initials": "KAP",
            "lastname": "Schultz"
        }
    ],
    "conclusions": "Outcomes were worse for patients with FIGO stage\u00a0\u2265IC2 disease and for tumors with >19 mitoses per 10 HPF. Given the prognostic significance of MI, the authors strongly recommend the assessment of MI for all juvGCTs. More information about tumor biology is critical to identify which patients may benefit from adjuvant chemotherapy and to facilitate the development of novel therapies.",
    "copyrights": "\u00a9 2025 American Cancer Society.",
    "doi": "10.1002/cncr.35862",
    "journal": "Cancer",
    "keywords": [
        "juvenile granulosa cell tumor",
        "mitotic index",
        "ovarian tumor",
        "pediatric cancer",
        "rare cancer",
        "sex cord\u2010stromal tumor"
    ],
    "methods": null,
    "publication_date": "2025-04-23",
    "pubmed_id": "40267023",
    "results": "In total, 70 patients with juvGCT enrolled and were diagnosed between 2001 and 2024; most patients (81%, 57 of 70) presented with FIGO stage I disease. Adjuvant chemotherapy was given in 30% (21 of 70); all regimens were platinum-based. Three-year event-free survival among patients with stage IA tumors was 80.2% (95% confidence interval [CI], 62.4%-100.0%), IC1 was 87.4 (95% CI, 72.4%-100.0%), IC2-IC3 was 63.6% (95% CI, 40.7%-99.5%), and II-IV was 48% (95% CI, 24.6%-93.8%). Of the patients with recurrent juvGCT with known mitotic index (MI), all had MI greater than 19 mitoses per 10 high power fields (HPF) at diagnosis.",
    "title": "Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries.",
    "xml": "<Element 'PubmedArticle' at 0x78850521f150>"
}